Givosiran Sodium, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

Patisiran sodium, a pioneering therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

Inclisiran sodium is a novel small interfering RNA (siRNA) therapeutic developed by Alnylam Pharmaceuticals and commercialized by Novartis.

Cemdisiran, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals in collaboration with Sanofi.

Nedosiran, also known by its brand name RIVFLOZA, is an innovative RNA interference (RNAi) therapeutic developed by Dicerna Pharmaceuticals.

Tivanisiran is an innovative small interfering RNA (siRNA) therapeutic agent developed by Sylentis, a Spanish biopharmaceutical company specializing in RNAi technology.

Fitusiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals in collaboration with Sanofi Genzyme.

The role of Artificial Intelligence (AI) in the design of small nucleic acid drugs is becoming increasingly prominent.

Ravulizumab is composed of two types of polypeptide chains, light and heavy chains, which are typical of monoclonal antibodies.

Structurally, mylotarg is characterized by its humanized IgG4 backbone, which contributes to its stability and reduced immunogenicity.

The application of AI in drug discovery can reduce the development timeline and increase the success rate of new drugs from 12% to 14%.

Lumasiran works by specifically binding to HAO1 mRNA and promoting its degradation, thereby reducing the synthesis of GO enzyme.